NASDAQ:ERNA - US1140823089 - Common Stock
The current stock price of ERNA is 1.41 USD. In the past month the price decreased by -14.1%. In the past year, price decreased by -94.08%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 20.05 | 375.04B | ||
AMGN | AMGEN INC | 12.98 | 152.43B | ||
GILD | GILEAD SCIENCES INC | 14.56 | 139.86B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 23.33 | 101.32B | ||
REGN | REGENERON PHARMACEUTICALS | 12.66 | 61.23B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 58.91B | ||
ARGX | ARGENX SE - ADR | 76.77 | 43.55B | ||
ONC | BEONE MEDICINES LTD-ADR | 6.81 | 40.17B | ||
INSM | INSMED INC | N/A | 30.44B | ||
BNTX | BIONTECH SE-ADR | N/A | 24.13B | ||
NTRA | NATERA INC | N/A | 23.19B | ||
BIIB | BIOGEN INC | 8.81 | 20.67B |
Ernexa Therapeutics, Inc. engages in the provision of cell engineering therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 6 full-time employees. The firm is focused on using cutting-edge gene-editing tools to deliver safe off-the-shelf cell therapies for the treatment of advanced solid tumors. Its Pipeline includes ERNA-101, and ERNA-102. Its core technology utilizes engineer allogenic-induced pluripotent stem cells (iPSCs) to express genes of interest and to efficiently differentiate these cells into mesenchymal stem cells (iMSCs). The firm seeks to capitalize on the intrinsic tumor-homing ability of MSCs to slip through the tumor’s defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment (TME), thus unleashing potent anti-cancer immune responses. The firm is focused on developing iPSC-derived iMSC that express critical factors, such as pro-inflammatory cytokines.
ERNEXA THERAPEUTICS INC
1035 Cambridge Street, Suite 18A
Cambridge MASSACHUSETTS US
Employees: 6
Phone: 16177986700
The current stock price of ERNA is 1.41 USD. The price increased by 5.22% in the last trading session.
The exchange symbol of ERNEXA THERAPEUTICS INC is ERNA and it is listed on the Nasdaq exchange.
ERNA stock is listed on the Nasdaq exchange.
ERNEXA THERAPEUTICS INC (ERNA) has a market capitalization of 10.81M USD. This makes ERNA a Nano Cap stock.
ERNEXA THERAPEUTICS INC (ERNA) currently has 6 employees.
ERNEXA THERAPEUTICS INC (ERNA) has a resistance level at 1.73. Check the full technical report for a detailed analysis of ERNA support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ERNA does not pay a dividend.
ERNEXA THERAPEUTICS INC (ERNA) will report earnings on 2025-11-10.
ERNEXA THERAPEUTICS INC (ERNA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-78.93).
The outstanding short interest for ERNEXA THERAPEUTICS INC (ERNA) is 1.6% of its float. Check the ownership tab for more information on the ERNA short interest.
ChartMill assigns a fundamental rating of 2 / 10 to ERNA. While ERNA seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months ERNA reported a non-GAAP Earnings per Share(EPS) of -78.93. The EPS decreased by -18.99% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -576.48% | ||
ROE | -983.8% | ||
Debt/Equity | 0 |